Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

WIL Research Acquires Ricerca Facility in Lyon, France

Published: Friday, June 21, 2013
Last Updated: Friday, June 21, 2013
Bookmark and Share
The addition of the 18,000-square meter facility fortifies WIL Research’s service offerings in Europe.

“As we listened to our clients and analyzed emerging trends in the pharmaceutical marketplace, it became clear that expansion of our biologic capabilities in Europe was the right move for us,” said David Spaight, WIL Research’s Chairman and Chief Executive Officer. “The Lyon operation leverages our existing capabilities in the United States and the Netherlands and creates a powerful new platform to deliver exceptional value to our clients. This definitive acquisition will double our capacity in Europe, strengthen our offerings to clients and enable WIL Research to accelerate the healthy growth rate we have achieved over the past three years in a challenging market environment.”

Dr. Michael Placke, President, Ricerca Biosciences LLC, explained, “This divestiture will fund significant capital investment into our Concord, Ohio business allowing us to expand and re-invigorate our integrated drug development services in chemical development, drug substance production, and drug safety and metabolism”.

Renamed WIL Research Europe - Lyon, the lab will retain its approximately 280 employees. Long-time Managing Director of the facility, Stéphane Bulle, will continue to lead the site and keep his current senior leadership team intact.

With the expansion, WIL Research strengthens its global position as a highly credible player serving the pharmaceutical and chemical industries and its commitment to client needs for nimbleness and customized services.

“While this acquisition expands our integrated safety assessment and associated services for pharmaceutical companies, it also enables us to enhance our focus on the chemical and agrochemical industries via our expert scientific staff in Den Bosch, The Netherlands,” added Spaight.

Over the past 45 years, the Lyon facility has developed a strong scientific reputation with European pharmaceutical clients in safety pharmacology and specialized services including continuous infusion and developmental and reproductive toxicology.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

WIL Research Partners with Three S Japan
Partnership to expand full portfolio of global safety assessment services to the Japanese market.
Friday, May 24, 2013
Scientific News
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Adipose Tissue Secretes Factors That Activate Metabolism
Study finds brown adipose tissue secretes signalling factors that activates metabolism of fat and carbohydrates.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
Developing Novel Ear Infection Treatments
Research team engineers antibiotic gel for treating middle ear infections.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!